DUBLIN , Sept. 23, 2022 /PRNewswire/ -- The "Global Markets for Insulin Drug and Delivery Technologies" report has been added to ResearchAndMarkets.com's offering.
The current report will provide an in-depth look at the insulin drug and delivery technologies market. This report analyzes the market trends of insulin drug and delivery technologies with data from 2021, estimates from 2022, projections of compound annual growth rates through 2027 (forecast period 2022-2027), and regional markets of the insulin drug and delivery technologies.
This report will highlight the current and future market potential of insulin drug and delivery technologies along with a detailed analysis of the competitive environment. Regulatory scenarios, drivers, restraints and opportunities will be covered in the current report. The report also covers market projections for 2026 and market share for key market players.
Insulin drug and delivery technologies are used to manage type 1 and type 2 diabetes. Expedient insulin delivery devices such as smart pens help diabetes patients optimize blood glucose control and minimize the risk of associated health issues. Advanced insulin delivery devices offer better patient conformity. The traditional syringes and insulin pumps are being replaced by reusable and disposable insulin pens due to the latter's portability, greater dosage accuracy, built-in memory, larger dosages and ease of use. There have been no major breakthrough in traditional syringes and pumps. Major makers of insulin delivery devices include Medtronic, F. Hoffmann-La Roche (Roche) Ltd., Becton Dickinson (BD), Ypsomed AG and B. Braun Melsungen AG. Key manufacturers of modern insulin and human insulin include Sanofi, Eli Lilly, Novo Nordisk, Boehringer Ingelheim International GmbH, Biocon and Viatris Inc. Market growth is attributed to factors such as the increasing incidence of diabetes and novel insulin drug and delivery technologies. The global market for insulin drug and delivery technologies is segmented by device type, insulin type and region.
In this report, the market has been segmented based on device type, insulin type and geographic region. Device types include syringes, insulin pens, insulin pumps, smart pens and others. Insulin types include long-acting, rapid-acting, premixed insulins, intermediate-acting and short-acting.
Geographic regions covered include North America , Europe , Asia-Pacific and the rest of the world (RoW). Individual countries covered include the U.S., Germany , the U.K., Italy , France , Japan , China and India .
Descriptive company profiles of key manufacturers of modern insulin and insulin delivery devices, including Sanofi, Eli Lilly, Novo Nordisk, Medtronic, F. Hoffmann-La Roche (Roche) Ltd., Becton Dickinson (BD), Ypsomed AG and B. Braun Melsungen AG
24 data tables and 31 additional tables
An up-to-date review of the global markets for insulin drug and delivery technologies
Analyses of the global market trends, with historic market revenue (sales data) for 2020 and 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
Highlights of the current state of the insulin drug and delivery industry structure, novel technological updates and issues surrounding insulin pens and insulin syringes, ongoing research activities, and regulatory and pricing scenarios
Estimation of the actual market size and market forecast for insulin drug and delivery technologies, and corresponding market share analysis by device type, insulin type, and geographic region
Updated information on the key merger and acquisition deals, partnerships, collaborations and other strategic alliances within the insulin drug and delivery technologies industry
Analysis of market opportunities with a holistic review of the Porter's Five Forces analysis model considering both the micro and macro environmental factors prevailing in the market
Identification of the major stakeholders and analysis of the competitive landscape based on recent developments and segmental revenues
Chapter 1 Introduction 1.1 Insulin Overview 1.2 Diabetes Overview 1.2.1 Disease Symptoms and Risk Factors 1.2.2 Epidemiology and Economic Burden 1.3 Study Goals and Objectives 1.4 Reasons for Doing this Study 1.5 What's New in this Update? 1.6 Scope of Report 1.7 Information Sources 1.8 Methodology 1.9 Geographic Breakdown 1.10 Analyst's Credentials 1.11 Custom Research 1.12 Related Research Reports Chapter 2 Summary and Highlights Chapter 3 Market Dynamics 3.1 Market Drivers 3.1.1 Rising Prevalence of Diabetes 3.1.2 Smart Insulin Drug Delivery Technologies 3.1.3 Painless Insulin Drug Delivery Technologies 3.2 Market Restraints 3.2.1 Product Recalls 3.3 Market Opportunities 3.3.1 Inorganic Strategies Amongst Market Players Chapter 4 Market Overview 4.1 Market Insights 4.1.1 Insulin 4.1.2 Diabetes 4.2 Current Market Trends 4.2.1 Recent Product Introductions 4.2.2 Recent Strategic Alliances 4.3 Future Perspective Chapter 5 Regulatory Landscape and Reimbursement Scenario 5.1 Regulatory Landscape 5.1.1 U.S. Regulations for Medical Devices 5.1.2 U.S. Drug Regulations 5.1.3 European Regulations for Medical Devices 5.1.4 European Regulations for Drugs 5.1.5 Asia-Pacific Regulations for Medical Devices 5.2 Reimbursement Scenario 5.2.1 Pricing and Reimbursement Overview 5.2.2 Pricing and Reimbursement for Medical Devices 5.2.3 Pricing and Reimbursement for Pharmaceuticals 5.3 Insurance 5.3.1 Insurance for Diabetic Emergencies Chapter 6 Impact of Covid-19 on Market 6.1 Overview 6.2 Covid-19 Crisis 6.2.1 Impact on Market for Insulin Drug and Delivery Technologies 6.2.2 Covid-19 Measures Chapter 7 Market Breakdown by Device Type 7.1 Insulin Delivery Technologies 7.1.1 Syringes 7.1.2 Insulin Pens 7.1.3 Insulin Pumps 7.1.4 Smart Pens 7.1.5 Others Chapter 8 Market Breakdown by Insulin Type 8.1 Insulin 8.1.1 Structure of Insulin 8.1.2 Insulin Biosynthesis 8.1.3 Insulin Types Chapter 9 Market Breakdown by Region 9.1 Overview 9.1.1 North America 9.1.2 Europe 9.1.3 Asia-Pacific 9.1.4 Rest of the World Chapter 10 Analysis of Market Opportunities 10.1 Porter's Five Forces Analysis 10.1.1 Threat of New Entrants 10.1.2 Threat of Substitutes 10.1.3 Bargaining Power of Suppliers 10.1.4 Bargaining Power of Buyers 10.1.5 Degree of Competition Chapter 11 Competitive Landscape Chapter 12 Company Profiles 12.1 Major Companies
For more information about this report visit https://www.researchandmarkets.com/r/qw0qyx
Research and Markets Laura Wood , Senior Manager press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/global-insulin-drug-and-delivery-technology-market-analysis-report-2022-rising-prevalence-of-diabetes-smart-insulin-drug-delivery-technologies--painless-insulin-drug-delivery-technologies-301631950.html
(Bloomberg) -- Next week’s elections in Brazil pose a challenge to Petrobras investors. Former President Luiz Inacio Lula da Silva, the front-runner, has vowed to use the company as a vehicle for national development. Incumbent Jair Bolsonaro, who’s fighting for a come-from-behind upset, is proposing the complete opposite, with plans to privatize the state-run giant.Most Read from BloombergBank of England Says Paper Banknotes Only Good for One More WeekRisk Assets Crushed With Few Signs Drama Is
Roku (NASDAQ: ROKU) faces a challenging scenario in the near term due to supply chain disruptions and inflation. However, it has this powerful tailwind at its back over the longer term. In this video, I will highlight how this could help Roku's stock bounce higher.
At a companywide all-hands meeting this week, Alphabet Inc (NASDAQ: GOOG) (NASDAQ: GOOGL) chief Sundar Pichai juggled tough questions from employees regarding cuts to travel and entertainment budgets, managing productivity, and potential layoffs. Employees questioned why Google is "nickel-and-diming employees" by cutting travel and swag budgets despite record profits and substantial cash reserves as it did after the pandemic. Pichai emphasized acting responsibly to tide through such critical sit
Crypto markets are down sharply after Fed Chair Jerome Powell and JPMorgan CEO Jamie Dimon both voiced regulatory concerns earlier this week.
The comments made by CFO Richard Galanti on its conference call suggest the Fed will still be in inflation-fighting mode for the rest of the year
Yahoo Finance Live anchors discuss Google CEO Sundar Pichai's comments to employees at an all-hands meeting amid cost-cutting measures.
Indian refiners may skip buying Russia’s ESPO blend of crude oil in September, apparently due to high freight charges.
Shares of virtually all oil and gas stocks crashed today, with even those regarded as among the "safest" oil and gas stocks plunging in value. Diversified integrated major and Warren Buffett favorite Chevron (NYSE: CVX) fell 5%, pipeline company Enterprise Products Partners (NYSE: EPD) fell 5.3%, and shale explorer and producer Diamondback Energy (NASDAQ: FANG) fell a whopping 9.5% as of 1:15 p.m. ET. All of these oil and gas-related stocks seem to be following the plunge in oil prices, as November oil futures fell 5.5% at that time to $78.90 as of this writing, similar to the first two stocks.
The blue oval brand has set itself the ambition of producing 2 million electric vehicles globally per year by the end of 2026. In 2021, the group only manufactured 27,140 electric vehicles in the United States. This means that reaching 2 million units five years later is a huge challenge even when your name is Ford, a company that has been producing and selling vehicles around the world for several decades.
Marko Papic, the ClockTower Group’s chief strategist, argues the real risk to oil and gasoline prices comes from Iraq amid rising tensions in the Middle East.
UBS analysts upgraded Eli Lilly stock to Buy, stating that the pharma company's Type 2 diabetes medication could become a best-selling drug.
Coal stocks have paused but still lead all other industries so far in 2022 — seemingly bucking analyst predictions that coal is dead.
During his testimony to Congress on Wednesday, JPMorgan CEO Jamie Dimon criticized cryptocurrencies like bitcoin, comparing them to Ponzi schemes.
While sentiment in oil markets has been decidedly bearish of late, Russia’s escalation of its war in Ukraine and the opening up of China provide major upside potential for oil
Yahoo Finance Live anchors discuss BMO's note on Domino's Pizza and the outlook for pizza chains throughout football season.
Tesla (TSLA) job postings reveal the electric vehicle maker is doubling down on humanoid robots.
The car company has run into supply constraints with the brand-name badges and the nameplates that specify the model, important identifiers for the auto maker’s products.
Nvidia (NVDA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Weakening growth and a strengthening dollar are weighing on crude prices, which are near the level they started the year.
Elizabeth Warren bears down on reimbursing Zelle customers cheated by scammers, while GOP senators push back on banks' liberal social policies.